Keytruda – Health

FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC

Print this page KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not… Read More »

Merck suits up for another Opdivo showdown with Keytruda liver cancer approval

Merck just advanced the Keytruda-Opdivo immuno-oncology rivalry into a brand-new arena. On Friday, the FDA handed Keytruda a new approval in patients with hepatocellular carcinoma—the most common form of liver cancer in adults—who have already been treated with Bayer’s Nexavar. That’s a group for which regulators cleared Opdivo, Keytruda’s chief nemesis in the PD-1/PD-L1 class,… Read More »